Omeros Corporation ( Omeros, the Company or we ) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Our complement-targeted product, product candidates, and ther…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
$125M
▲ +97.9% YoY
Op. Margin
–
ROIC
-89.75%
▼ -5.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$69M
▲ +22.0% YoY
Op. Cash Flow (TTM)
-$69M
▲ +22.0% YoY
Net Debt
-$132M
Net Cash Position
Cash & Equiv.
$132M
3Y CAGR: +4.4%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with OMER
Held by ETFs
OMER is in 32 US ETFs. The largest of them, with OMER's weight in each:
Omeros (OMER) in three numbers
Questions about Omeros
Is Omeros (OMER) overvalued?
Omeros trades at 10.51 times earnings. Intrinsiqq's fair value calculator has no opening value for OMER, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Omeros a high-quality business?
Omeros scores 27 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is net debt at -$132M, and its weakest is return on capital at -89.8%. The Quality tab shows every check against its target.
Does Omeros (OMER) pay a dividend?
No. Omeros (OMER) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.8% buyback yield. The Dividends tab shows its cash returns.
Source: 10-Q filed 7 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in OMER's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OMER
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.